DBV Technologies SA – American (DBVT) Gets a Hold Rating from Stifel Nicolaus


Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on DBV Technologies SA – American (DBVT) yesterday and set a price target of $10. The company’s shares opened today at $8.75.

Archila noted:

“We are reiterating our Hold rating on DBVT shares after the company provided its 4Q18 business and financial update. We revise our model accordingly. As we indicated in our AAAAI recap/KOL dinner note, while the ICER analysis evaluating the cost effectiveness of peanut immunotherapies could pose a headwind for both DBVT and AIMT (Hold, $25.48), we do think the risk/reward for DBVT is probably more favorable at these levels if management is able to re-file its BLA on time in 3Q19, gain BLA acceptance from the FDA and its Adcom is eventually positive. With that said, we remain on the sidelines for now until management executes on its near-term regulatory initiatives and addresses its current capital overhang. We maintain our Hold rating and $10 target price.”

According to TipRanks.com, Archila has 0 stars on 0-5 star ranking scale with an average return of -6.1% and a 36.4% success rate. Archila covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Selecta Biosciences, and Heron Therapeutics.

The word on The Street in general, suggests a Hold analyst consensus rating for DBV Technologies SA – American with a $12.71 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $25.77 and a one-year low of $3.60. Currently, DBV Technologies SA – American has an average volume of 847.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts